Novel Therapies for Aggressive B-Cell Lymphoma

Abstract EN

Aggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL).

DLBCL, with its 3 subtypes, is the most common type of lymphoma.

Advances in chemoimmunotherapy have substantially improved disease control.

However, depending on the subtype, patients with DLBCL still exhibit substantially different survival rates.

In MCL, a mature B-cell lymphoma, the addition of rituximab to conventional chemotherapy regimens has increased response rates, but not survival.

Burkitt lymphoma, the most aggressive BCL, is characterized by a high proliferative index and requires more intensive chemotherapy regimens than DLBCL.

Hence, there is a need for more effective therapies for all three diseases.

Increased understanding of the molecular features of aggressive BCL has led to the development of a range of novel therapies, many of which target the tumor in a tailored manner and are summarized in this paper.